Options for patients with irritable bowel syndrome: contrasting traditional and novel serotonergic therapies (Q35985391)

11 August 2017

1 reference

title

Options for patients with irritable bowel syndrome: contrasting traditional and novel serotonergic therapies (English)

1 reference

11 August 2017

irritable bowel syndrome

1 reference

Johanson JF

1

1 reference

11 August 2017

1 December 2004

1 reference

Neurogastroenterology and Motility

11 August 2017

1 reference

11 August 2017

16

1 reference

11 August 2017

6

1 reference

11 August 2017

701-711

1 reference

AGA technical review on irritable bowel syndrome

11 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2004.00550.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2004.00550.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2004.00550.X

Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2004.00550.X

Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2004.00550.X

Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2004.00550.X

Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2004.00550.X

Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2004.00550.X

Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2004.00550.X

Comorbidity of gastrointestinal complaints, depression, and anxiety in the Epidemiologic Catchment Area (ECA) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2004.00550.X

Gut-focused hypnotherapy normalizes disordered rectal sensitivity in patients with irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2004.00550.X

Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2004.00550.X

Patients with constipation-predominant irritable bowel syndrome (IBS) may have elevated serotonin concentrations in colonic mucosa as compared with diarrhea-predominant patients and subjects with normal bowel habits

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2004.00550.X

Role of nerves in enteric infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2004.00550.X

Serotonin availability is increased in mucosa of guinea pigs with TNBS-induced colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2004.00550.X

Brain responses to visceral and somatic stimuli in patients with irritable bowel syndrome with and without fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2004.00550.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2004.00550.X

The 5-HT(3) receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetised rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2004.00550.X

Changes in pyloric resistance induced by erythromycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2004.00550.X

Serotonin type-4 receptors modulate the sensitivity of intramural mechanoreceptive afferents of the cat rectum

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2004.00550.X

Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2004.00550.X

Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2004.00550.X

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2004.00550.X

A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2004.00550.X

Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2004.00550.X

Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2004.00550.X

A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2004.00550.X

Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2004.00550.X

An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2004.00550.X

Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2004.00550.X

Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2004.00550.X

Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2004.00550.X

Improving the Quality of Reports of Meta-Analyses of Randomised Controlled Trials: The QUOROM Statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2982.2004.00550.X

10.1111/J.1365-2982.2004.00550.X

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference

PubMed ID

15601419